Molecular Diagnostics for Transplant Market

There has been an increasing prevalence of infectious diseases owing to various factors such as climate change, rapid urbanization, microbial evolution, among others. Special care needs to be taken before transplantation as a transplant patient can get any type of infection caused by bacteria, viruses, fungi and parasites. These include influenza virus infection, urinary tract infection, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr virus, Human herpesvirus 6, among several others. Moreover, increasing antimicrobial resistance is also a cause of serious concern and has been adding to the increasing prevalence of infectious disease.

For instance, according to the Centers for Disease Control and Prevention, more than 2.8 million antimicrobial-resistant infections occur in the US each year. Thus, increasing prevalence of infectious disease has driven the demand for implementation of thorough molecular diagnostics in transplantation, thereby, driving the market.

Moreover, the number of patients suffering from various types of cancers such as lung, blood, breast, and liver is increasing worldwide. In 2020, according to GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer (IARC), an estimated number of 19.3 million new cancer cases and about 10 million cancer deaths occurred globally.

Hence, the growing number of cancer patients and rising incidences of infectious diseases are increasing the demand for organ transplantation.

The Global Molecular Diagnostics for Transplant Market Industry is projected to experience substantial growth over the next decade. With a market value of 0.86 USD Billion in 2024, it is anticipated to expand to 2.15 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 8.66% from 2025 to 2035, driven by various factors including technological advancements, increasing transplant procedures, and heightened awareness of personalized medicine. The market's expansion reflects the critical role of molecular diagnostics in enhancing transplant outcomes and patient care.

The growing incidence of infectious diseases poses a challenge for transplant recipients, thereby driving the Global Molecular Diagnostics for Transplant Market Industry. Transplant patients are particularly vulnerable to infections due to immunosuppressive therapies, necessitating the need for rapid and accurate diagnostic tools to detect infections early. The demand for molecular diagnostics that can identify pathogens quickly and effectively is increasing, as timely intervention is crucial for patient survival. This trend is expected to contribute to market growth, as healthcare providers seek reliable diagnostic solutions to manage the health of transplant patients.

The increasing emphasis on personalized medicine is shaping the Global Molecular Diagnostics for Transplant Market Industry. Healthcare providers and patients are becoming more aware of the benefits of tailored treatment plans based on genetic and molecular profiles. This shift towards individualized care enhances the effectiveness of transplant procedures and minimizes the risk of complications. As a result, the demand for molecular diagnostics that can provide insights into patient-specific responses to treatment is on the rise. This trend is expected to contribute significantly to the market's growth, as healthcare systems increasingly adopt personalized approaches to transplant management.

Government initiatives and funding for research in the field of molecular diagnostics are pivotal for the Global Molecular Diagnostics for Transplant Market Industry. Regulatory bodies are increasingly recognizing the importance of molecular diagnostics in improving transplant outcomes, leading to streamlined approval processes for new diagnostic tools. Additionally, public and private funding for research and development in this area is on the rise, fostering innovation and accelerating the introduction of advanced diagnostic solutions. This supportive environment is likely to enhance market growth, as new technologies and methodologies are developed to address the complexities of transplant medicine.

The rising incidence of organ transplant procedures globally is a primary driver for the Global Molecular Diagnostics for Transplant Market Industry. As more patients require organ transplants due to conditions such as end-stage renal disease and liver failure, the demand for effective diagnostic tools increases. In 2024, the market is valued at approximately 0.86 USD Billion, reflecting the urgent need for precise molecular diagnostics to ensure successful transplant outcomes. This trend is expected to continue, with projections indicating that the market could reach 2.15 USD Billion by 2035, highlighting the critical role of molecular diagnostics in managing transplant patients.

Innovations in molecular diagnostic technologies significantly enhance the capabilities of the Global Molecular Diagnostics for Transplant Market Industry. Advances such as next-generation sequencing and real-time PCR allow for more accurate and rapid detection of organ rejection and infection. These technologies facilitate personalized medicine approaches, improving patient outcomes and reducing healthcare costs. The integration of artificial intelligence in diagnostic processes further streamlines workflows and enhances accuracy. As these technologies evolve, they are likely to drive market growth, contributing to a projected compound annual growth rate of 8.66% from 2025 to 2035.

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America molecular diagnostics for transplant market accounted for the largest market share in 2021, due to rising demand technology evolution and increasing incidences of chronic diseases that lead to an increase in organ transplants. According to research, the number of kidneys, liver, heart, lung, pancreas, and intestine transplants is increasing in the US, while the number of kidney transplants is increasing in Canada.

Further, the major countries studied are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%)  BY REGION 2023

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe molecular diagnostics for transplant market accounts for the second-largest market share owing to the rising prevalence of chronic diseases, including kidney, cardiovascular diseases (CVD), and respiratory diseases. Advancements in molecular diagnostics have improved the identification and understanding of specific gene defects for the appropriate organ transplant in kidney, heart, and lung failure. CVD diseases are influenced by factors such as atherosclerosis, blood clots, diabetes, a sedentary lifestyle, and obesity, which may lead to cardiac failure. In 2019, the European Society of Cardiology (ESC) Atlas estimated that Europe reports 11 million new cases suffering from CVD each year.

Furthermore, the Germany molecular diagnostics for transplant market held the largest market share, and the UK molecular diagnostics for transplant market was the second largest to hold the market share in the Europe region.

The Asia-Pacific molecular diagnostics for transplant market is expected to grow at a significant share from 2022 to 2030. The region's growing geriatric population demands organ transplantation, which may vary as per organ failure. In 2020, according to the World Economic Forum, China, India, and Japan had the oldest populations globally. Furthermore, it has been estimated that by 2050, one in four aged people will be living in the region. Moreover, China molecular diagnostics for transplant market held the largest market share, and the India molecular diagnostics for transplant market was the fastest growing market in the Asia-Pacific region.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the molecular diagnostics for transplant market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the molecular diagnostics for transplant industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Thermo Fisher Scientific Inc. (US) specializes in various biotechnology products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, and specialty diagnostics. The company helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to the market, and increase the laboratory's productivity. In September 2021, the company announced a new addition to its transplant diagnostics portfolio (a rapid next-generation sequencing assay that will provide high-resolution data in five hours). This new product enabled transplant laboratories to characterize samples better and bring speed and confidence to the transplant laboratory.